Witnessing the stock’s movement on the chart, on March 04, 2021, Cidara Therapeutics Inc. (NASDAQ: CDTX) set off with pace as it heaved 4.93% to $2.34. During the day, the stock rose to $2.38 and sunk to $2.13 before settling in for the price of $2.23 at the close. Taking a more long-term approach, CDTX posted a 52-week range of $1.30-$4.45.
Meanwhile, its Annual Earning per share during the time was 5.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -27.60%. This publicly-traded company’s shares outstanding now amounts to $44.17 million, simultaneously with a float of $35.34 million. The organization now has a market capitalization sitting at $110.10 million. At the time of writing, stock’s 50-day Moving Average stood at $2.40, while the 200-day Moving Average is $3.00.
It is quite necessary to find out the efficiency of the corporate organization, which has 68 number of employees on its payroll. It has generated 307,574 per worker during the last fiscal year. Meanwhile, its income per employee was -604,294. The stock had 7.54 Receivables turnover and 0.28 Total Asset turnover. For the Profitability, stocks operating margin was -199.49 and Pretax Margin of -196.47.
Cidara Therapeutics Inc. (CDTX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Cidara Therapeutics Inc.’s current insider ownership accounts for 0.90%, in contrast to 59.80% institutional ownership. According to the most recent insider trade that took place on Nov 10, this organization’s President & CEO bought 50,000 shares at the rate of 2.00, making the entire transaction reach 100,015 in total value, affecting insider ownership by 347,878. Preceding that transaction, on Nov 10, Company’s Chief Financial Officer bought 50,000 for 2.01, making the whole transaction’s value amount to 100,720. This particular insider is now the holder of 50,000 in total.
Cidara Therapeutics Inc. (CDTX) Earnings and Revenue Records
As on 12/30/2020, Multinational firm has announced its last quarter scores, in which it reported -$0.49 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.24) by -$0.25. This company achieved a net margin of -196.47 while generating a return on equity of -84.75. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
Cidara Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -27.60% and is forecasted to reach -1.40 in the upcoming year.
Cidara Therapeutics Inc. (NASDAQ: CDTX) Trading Performance Indicators
Let’s observe the current performance indicators for Cidara Therapeutics Inc. (CDTX). It’s Quick Ratio in the last reported quarter now stands at 1.50. The Stock has managed to achieve an average true range (ATR) of 0.24. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.79.
In the same vein, CDTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.65, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -1.40 at the market close of one year from today.
Technical Analysis of Cidara Therapeutics Inc. (CDTX)
Going through the that latest performance of [Cidara Therapeutics Inc., CDTX]. Its last 5-days volume of 1.07 million was inferior to the volume of 1.08 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 21.69% While, its Average True Range was 0.23.
Raw Stochastic average of Cidara Therapeutics Inc. (CDTX) in the period of the previous 100 days is set at 35.64%, which indicates a major rise in contrast to 20.59% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 99.06% that was higher than 81.62% volatility it exhibited in the past 100-days period.